144 related articles for article (PubMed ID: 38051408)
1. The role of endocrine treatment on the risk of developing an ipsilateral invasive breast cancer in hormone receptor positive patients with ductal carcinoma in situ.
Altundag K
Breast Cancer Res Treat; 2024 Feb; 204(1):189-190. PubMed ID: 38051408
[No Abstract] [Full Text] [Related]
2. Cytological criteria for the diagnosis of intraductal hyperplasia, ductal carcinoma in situ, and invasive carcinoma of the breast.
Bofin AM; Lydersen S; Hagmar BM
Diagn Cytopathol; 2004 Oct; 31(4):207-15. PubMed ID: 15452908
[TBL] [Abstract][Full Text] [Related]
3. A practical approach to breast ductal carcinoma in situ and tumors with an extensive intraductal component.
King JM
Pathology; 1994 Apr; 26(2):90-3. PubMed ID: 8090601
[TBL] [Abstract][Full Text] [Related]
4. Pathobiological considerations relating to the treatment of intraductal carcinoma (ductal carcinoma in situ) of the breast.
Fisher ER
CA Cancer J Clin; 1997; 47(1):52-64. PubMed ID: 8996078
[TBL] [Abstract][Full Text] [Related]
5. Possible Prognostic Role of HER2/Neu in Ductal Carcinoma In Situ and Atypical Ductal Proliferative Lesions of the Breast.
Daoud SA; Ismail WM; Abdelhamid MS; Nabil TM; Daoud SA
Asian Pac J Cancer Prev; 2016; 17(8):3733-6. PubMed ID: 27644608
[TBL] [Abstract][Full Text] [Related]
6. Ductal carcinoma in situ with and without microinvasion: is there a clinically meaningful difference in outcome?
Canas-Marques R; Schnitt SJ
Br J Cancer; 2023 Mar; 128(5):713-714. PubMed ID: 36707635
[No Abstract] [Full Text] [Related]
7. Lobular neoplasia: frequency and association with other breast lesions.
Gomes DS; Balabram D; Porto SS; Gobbi H
Diagn Pathol; 2011 Aug; 6():74. PubMed ID: 21827679
[TBL] [Abstract][Full Text] [Related]
8. Tumour infiltrating lymphocytes and ductal carcinoma in situ: The art of thinking counterintuitively.
Salgado R; Fineberg S; De Caluwe A; de Azambuja E
Eur J Cancer; 2022 Jun; 168():138-140. PubMed ID: 35430150
[No Abstract] [Full Text] [Related]
9. ASO Author Reflections: Active Surveillance for Ductal Carcinoma In Situ (DCIS).
Oseni TO; Bahl M
Ann Surg Oncol; 2020 Oct; 27(11):4466-4467. PubMed ID: 32440718
[No Abstract] [Full Text] [Related]
10. Molecular evidence for progression of microglandular adenosis (MGA) to invasive carcinoma.
Shin SJ; Simpson PT; Da Silva L; Jayanthan J; Reid L; Lakhani SR; Rosen PP
Am J Surg Pathol; 2009 Apr; 33(4):496-504. PubMed ID: 19047897
[TBL] [Abstract][Full Text] [Related]
11. Comparison of magnetic resonance imaging and multidetector computed tomography for evaluating intraductal tumor extension of breast cancer.
Uematsu T
Jpn J Radiol; 2010 Oct; 28(8):563-70. PubMed ID: 20972855
[TBL] [Abstract][Full Text] [Related]
12. Active surveillance of women diagnosed with atypical ductal hyperplasia on core needle biopsy may spare many women potentially unnecessary surgery, but at the risk of undertreatment for a minority: 10-year surgical outcomes of 114 consecutive cases from a single center.
Farshid G; Edwards S; Kollias J; Gill PG
Mod Pathol; 2018 Mar; 31(3):395-405. PubMed ID: 29099502
[TBL] [Abstract][Full Text] [Related]
13. Is there a low-grade precursor pathway in breast cancer?
King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
[TBL] [Abstract][Full Text] [Related]
14. Regressive change in high-grade ductal carcinoma in situ of the breast: histopathologic spectrum and biologic importance.
Wasserman JK; Parra-Herran C
Am J Clin Pathol; 2015 Sep; 144(3):503-10. PubMed ID: 26276781
[TBL] [Abstract][Full Text] [Related]
15. The Landmark Series-Ductal Carcinoma in Situ: The Evolution of Treatment.
Nash AL; Hwang ES
Ann Surg Oncol; 2023 Jun; 30(6):3206-3214. PubMed ID: 37024766
[TBL] [Abstract][Full Text] [Related]
16. Is it rational to extend the duration of preventive endocrine treatment in hormone receptor positive ductal carcinoma in situ?
Altundag K
J BUON; 2018; 23(3):835. PubMed ID: 30003760
[No Abstract] [Full Text] [Related]
17. Surgical Excision Versus Neoadjuvant Radiotherapy Followed by Delayed Surgical Excision of Ductal Carcinoma In Situ (NORDIS).
Rossi AJ; Verbus EA; Horst K; De Martini W; Allison K; Hernandez JM; Wapnir IL
Ann Surg Oncol; 2022 Mar; 29(3):1528-1529. PubMed ID: 34471985
[No Abstract] [Full Text] [Related]
18. Papillary lesions of the breast.
Ibarra JA
Breast J; 2006; 12(3):237-51. PubMed ID: 16684322
[TBL] [Abstract][Full Text] [Related]
19. Ductal carcinoma in situ.
Swain SM
Cancer Invest; 1992; 10(5):443-54. PubMed ID: 1327429
[No Abstract] [Full Text] [Related]
20. Comparison of ipsilateral breast tumor recurrence after breast-conserving surgery between ductal carcinoma in situ and invasive breast cancer.
Choi YJ; Shin YD; Song YJ
World J Surg Oncol; 2016 Apr; 14():126. PubMed ID: 27122132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
